

Multimodal Protocol for Anticoagulation Monitoring in ECMO Patients: Safety Analysis of Anti-Xa and VCM Monitoring

Point of Care Testing May Have the Potential to Estimate Anti-Xa Values Without the Need for a Laboratory Test

DURHAM, NC, UNITED STATES,
November 11, 2024 /
EINPresswire.com/ -- Entegriion, Inc., a
leading developer of innovative
solutions for clinical diagnosis and



management of hemostasis, highlighted a newly presented study demonstrating the clinical value of its portable [Viscoelastic Coagulation Monitor](#) (VCM) in a safety analysis of Anti-Xa and the VCM. In the study, presented at the 2024 Extracorporeal Life Support Organization (ELSO)



The VCM continues to expand the availability of viscoelastic coagulation monitoring and treatment of hemostatic conditions patient side”

*Bert Valada, President and
CEO of Entegriion*

annual meeting, investigators from Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Department of Anesthesia, Critical Care and Emergency, Milan Italy and University of Milan Department of Pathophysiology and Transplantation, Milan, Italy, employed a modified [heparin anticoagulation algorithm](#) from aPTT to anti-Xa and the VCM. Over 163 ECMO-days (489 – observations) anti-Xa levels with daily VCM testing evaluated [anticoagulation efficacy](#).

Between December 2023 and July 2024 16 patients were enrolled. Preliminary data suggest that the new algorithm is safe with low rates of thrombotic and bleeding events.

“The VCM continues to expand the availability of viscoelastic coagulation monitoring and treatment of hemostatic conditions patient side,” said Bert Valada, President and CEO of Entegriion. “This recent study from Italy showed how the Entegriion VCM can play a significant role in helping support clinical decision-making and improving patient outcomes.”

About the Viscoelastic Coagulation Monitor (VCM)

The Entegriion VCM is a compact, portable device that performs a viscoelastic analysis of the coagulation-fibrinolysis process utilizing glass surface activation of untreated whole blood. The wide surface area of contact between the blood and the glass inside the cartridge accounts for the rapid initiation of clotting, eliminating the need for activating factors. VCM has been compared to ROTEM® NATEM (non-activated method), showing good-to-moderate agreement in test results between the two systems in a cohort of patients undergoing major surgery.¹



VCM Analyzer

By making viscoelastic measurements of the hemostasis of blood samples rapidly and accurately, the VCM system addresses the accessibility, robustness and training issues associated with large, complex, traditional systems. The Entegriion VCM has a CE mark for use in Europe and is available for research use only in the U.S .

About Entegriion

Entegriion is a life sciences development company that is focused on improving the safety and availability of blood component therapy. Based in North Carolina's Research Triangle Park, its patented technologies are designed to overcome limitations in storage, safety, and availability of blood-derived products while improving their functionality. Many of Entegriion's advances in biologics are based on close collaborations with leading medical research institutions. Visit www.entegriion-vcm.com for more information.

1. Brearton C, Rushton A, Parker J, Martin H, Hodgson J. Performance Evaluation of a New Point of Care Viscoelastic Coagulation Monitoring System in Major Abdominal, Orthopaedic and Vascular Surgery. *Platelets*. 2020;1–8.

Marketing

Entegriion, Inc.

info@entegriion.com

This press release can be viewed online at: <https://www.einpresswire.com/article/759609701>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

